WallStreetZenWallStreetZen

NASDAQ: BIAF
Bioaffinity Technologies Inc Earnings & Revenue

OverviewEarnings
DividendOwnership

BIAF past revenue growth

How has BIAF's revenue growth performed historically?
Company
52,627.44%
Industry
0.32%
Market
17.87%
BIAF's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BIAF's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BIAF's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BIAF earnings and revenue history

Current Revenue
$2.5M
Current Earnings
-$7.9M
Current Profit Margin
-313.4%

BIAF Return on Equity

Current Company
-107.2%
Current Industry
-24%
Current Market
188%
BIAF's Return on Equity (-107.2%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when BIAF announces earnings.

BIAF Return on Assets

Current Company
-84.1%
Current Industry
6.7%
BIAF is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

BIAF Return on Capital Employed

Current Company
-131.89%
Current Industry
11.6%
BIAF's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BIAF vs Diagnostic & Research Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
BIAF$2.53M-$7.63M-$7.94M+52,627.44%N/A
DRIO$20.35M-$54.38M-$63.51M+22.45%N/A
XGN$52.55M-$18.21M-$23.69M+10.13%N/A
AWH$9.15M-$16.50M-$16.69M+24.56%N/A
DMTK$15.30M-$95.04M-$100.89M+44.33%N/A
View Top Diagnostic & Research Stocks

BIAF earnings dates

Next earnings date
May 13, 2024

Bioaffinity Technologies Earnings & Revenue FAQ

What were BIAF's earnings last quarter?

On Invalid Date, Bioaffinity Technologies (NASDAQ: BIAF) reported Q4 2023 earnings per share (EPS) of -$0.26, up 218.18% year over year. Total Bioaffinity Technologies earnings for the quarter were -$2.37 million. In the same quarter last year, Bioaffinity Technologies's earnings per share (EPS) was $0.22.

If you're new to stock investing, here's how to buy Bioaffinity Technologies stock.

What was BIAF's earnings growth in the past year?

As of Q2 2024, Bioaffinity Technologies's earnings has grown year over year. Bioaffinity Technologies's earnings in the past year totalled -$7.94 million.

What is BIAF's earnings date?

Bioaffinity Technologies's earnings date is Invalid Date. Add BIAF to your watchlist to be reminded of BIAF's next earnings announcement.

What was BIAF's revenue last quarter?

On Invalid Date, Bioaffinity Technologies (NASDAQ: BIAF) reported Q4 2023 revenue of $2.21 million up 94,245.95% year over year. In the same quarter last year, Bioaffinity Technologies's revenue was $2.35 thousand.

What was BIAF's revenue growth in the past year?

As of Q2 2024, Bioaffinity Technologies's revenue has grown 52,627.44% year over year. This is 52,627.12 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 0.32%. Bioaffinity Technologies's revenue in the past year totalled $2.53 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.